ARQTArcutis Biotherapeutics, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~25% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What ARQT's price assumes
Arcutis Biotherapeutics, Inc. trades at 126× earnings against 18.8× for the median Biotechnology name, more expensive than its own group.
Trailing P/E · Biotechnology median 18.8 · 6.72× the median: the market pays up for this one
- Price / sales
- 7.20
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 1.2%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +25%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 15.1
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 93.7
- EV / salestoday's price, trailing year to Jun 30, 2026
- 6.92
- Healthcare median P/E509 names
- 26.2
- Biotechnology median P/E244 names
- 18.8
- Free cash flow, trailing twelve months
- $39M
- Market capitalisation
- $3.34B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.